Chronic pruritus is frequently refractory to currently available treatments. Studies suggest that pruritus may arise from an imbalance of the mu- and kappa-opioid receptor system activity in either the skin or the central nervous system. Stimulation of kappa-opioid receptors by their agonists inhibits pruritus in both animals and humans. The antipruritic effect of kappa-opioid receptor agonists can currently be assumed to be related to their binding to kappa-opioid receptors on keratinocytes and cutaneous and/or central itch neurones. To date, several case reports and 2 controlled trials have demonstrated a beneficial effect of systemic kappa-opioid receptor agonists in the treatment of uraemic pruritus, prurigo nodularis, paraneoplastic and cholestatic pruritus. Nalfurafine hydrochloride (Remitch®), a selective kappa-opioid receptor agonist, is approved for the treatment of chronic pruritus in Japan. The aim of this review is to provide an overview of the promising role of kappa-opioid receptors and their agonist in the pathophysiology and treatment of pruritus. Key words: itch; therapy; kappa opioid receptor antagonist; mu-opioid receptor.

(Accepted December 30, 2011.)

Acta Derm Venereol 2012; 92: 555–560.

Sonja Ständer, Competence Center Chronic Pruritus, Department of Dermatology, University Hospital Münster, Von-Esmarch-Strasse 58, DE-48149 Münster, Germany. E-mail: sonja.staender@ukmuenster.de

Chronic pruritus is frequently refractory to treatment. Accordingly, a symptomatic antipruritic therapy that would inhibit the induction, transmission, or perception of itch is badly needed. During the past 10 years, opioid receptors have been identified as a target in the treatment of pruritus. Mu- and kappa-opioid receptors are expressed in the skin and central nervous system (CNS) (1). Mu-opioid receptors (MOR) antagonists are effective in chronic pruritus of various origins (1). MOR and kappa-opioid receptors (KOR) mediate opposite effects (2). For example, activation of MOR inhibits pain, while activation of KOR inhibits itch. The newly developed KOR agonists have demonstrated in experimental and clinical studies antipruritic effects in antihistamine-resistant and antihistamine-sensitive pruritus in animals and humans (3, 4). Given that an imbalance of the endogenous opioid system has been considered as a pathomechanism in uraemic pruritus, antipruritic effects of KOR agonists have been investigated in randomized controlled trials (RCT) in this indication (5–8). The major advantage of the KOR agonists over MOR antagonists seems to be the fewer rates of up-to-date reported adverse events. MOR antagonists show a high rate of troublesome side-effects (1), hampering their application mainly in elderly patients. The aim of this paper is to provide an overview of the current knowledge of KOR and their role in pruritus as well as the evidence of antipruritic potency of KOR agonists and their possible use in the treatment of chronic pruritus.

METHODS

A systemic search for reports of KOR and KOR agonist in experimental animal models and studies in humans was carried out. The major electronic databases (PubMed, Ovid and DIMDI) were searched using the free-text key words kappa opioid receptor or kappa opioid receptor agonist, butorphanol, nalfurafine and/or skin, pruritus, itch, and several combinations of these words. Searching was carried out without time and language restriction, and without contacting manufacturers or authors. In addition, information on these two drugs from current data sheets was included.

RESULTS

A total of 3,183 papers (until August 2011) with the key word “kappa opioid receptor agonist” were found, mostly addressing the analgesic properties of KOR agonists. A combination of the key words “‘kappa opioid receptor agonist’” and “itch” or “pruritus” resulted in 28 papers, of which only 7 were case reports, case studies or randomized trials on antipruritic effects of KOR agonists in humans. In addition, we included papers on mechanisms of action, e.g. in animal models and experimental models as well as information from current data sheets of KOR agonists, finally resulting in 74 references.
Kappa opioid receptor expression

Opioid receptors (ORs) are a member of the pertussis toxin-sensitive heterotrimeric G<sub>i</sub>/G<sub>q</sub> protein-coupled receptor family with a 7 transmembrane domain and belong to the rhodopsin subfamily (9, 10). Three major classes of opioid receptors have been identified: KOR, MOR and delta-opioid receptors (DOR) (11–13). MOR is specific for the ligand beta-endorphin, DOR for enkephalins and KOR for dynorphins (Dyn) (14), but no ligand is completely specific for any receptor (15). It is assumed that 3 different subtypes of KOR (k1, k2 and k3) exist, based on ligand receptor binding studies, but only one has been identified so far (GenBank Acc. No. U11053) (16–22).

KOR is expressed in the CNS as well as in the periphery. In the CNS, KOR are localized in axons in the medial prefrontal cortex (23), in the nucleus accumbens, hypothalamic nuclei, periaqueductual gray (PAG), nucleus of the solitary tract, ventral tegmental area, amygdala, neocortex and supraspinal nucleus (24–26) and in the dorsal horn of the spinal cord (27). Interestingly, in the dorsal horn of the spinal cord, KOR may be linked with the cannabinoid system (28). Systemic application of the cannabinoid receptor agonist delta-9-tetrahydorcannabinol (THC) was demonstrated to inhibit nociceptive reflexes, possibly resulting from an inhibition of dorsal horn neurones through a KOR-dependent mechanism (28). KOR-expressing neurones are also located in the dorsal and trigeminal root ganglia (29), which is an important link to the peripheral nervous system. In the periphery, KOR has been detected in nerve terminals of muscles, joints and viscera (30). Expressed widely in the CNS and peripheral nervous system, the KOR system was shown to play an important role in anti-nociception (31), dysphoria (32, 33) and water diuresis (31, 33, 34).

KOR are expressed in human epidermal keratinocytes (35, 36) as well as dermal fibroblasts (36, 37) and mononuclear cells (37) as demonstrated in cell cultures (e.g. HaCaT, HNK) and skin biopsies on mRNA and protein levels. KOR expression in subepidermal nerve fibres was demonstrated by immunohistochemical staining (36). The corresponding KOR ligands DynA (1–17) and DynA (1–8) were identified in the epidermis (35). Studies suggest that KOR contribute to proliferation and differentiation of keratinocytes (38). For example, KOR knockout mice revealed epidermal hypotrophy and slightly enhanced cutaneous nerve fibre density after induction of dry skin dermatitis (38). The epidermis was significantly thinner than in wild-type mice (38). In addition, real-time polymerase chain reaction (PCR) showed increased KOR expression in epidermal keratinocytes and fibroblasts in hypertrophic scars in comparison with normal skin (36), which may contribute to the increased nociception in scars. Interestingly, a recent paper demonstrated that KOR expression was significantly decreased in the epidermis of itchy psoriatic patients compared with healthy controls (39). Psoriasis shows an epidermal hyperplasia, but no thinned epidermis. The reduced KOR expression argues against a role of KOR in differentiation of keratinocytes in patients with psoriasis. Further studies need to address the role of KOR in human keratinocyte biology (39). KOR are expressed on blood derived dendritic cells (40). In cell cultures (KOR transfected Jurkat T cells), activation of KOR down-regulates cytokines and chemokines in inflammatory cells, and thus could induce an anti-inflammatory response (41). This is of great interest for inflammatory diseases presenting with pruritus, such as atopic dermatitis (AD).

Role of kappa opioid receptor in pruritus

Like MOR, KOR plays a role in the sensation of itch in animals and humans (34, 42). Systemic administration of the selective and potent KOR antagonist norbinaltorphimine induced scratching in mice (42). In contrast, activation of itch neurones in the superficial layer of the dorsal horn of the spinal cord was shown to be inhibited by the KOR agonist TRK-820 (nalfurafine) in mice (43). Consequently, oral (3, 44) or subcutaneous (45, 46) administration of nalfurafine resulted in significant reduction of substance P (SP) or histamine-induced pruritus in wild-type mice. In addition, spontaneously developing scratching behaviour in NC/Nga mice could be suppressed by nalfurafine (3, 44–46). Scratching behaviour was reduced in KOR knockout mice after dry skin induction in comparison with wild-type mice (38). In a model of autoimmune-induced pruritus in aged MRL/lpr mice, oral nalfurafine also inhibited scratching behaviour (47). In a rat model of cholestatic pruritus, nalfurafine reduced scratching behaviour significantly (48). Intravenous application of TRK-820 suppressed scratching induced by systemic application of morphine in rhesus monkeys (49).

Together, KOR are involved in the pathophysiology of pruritus not only by their expression in the CNS, but also by their presence in the skin. For example, application of the peripherally acting KOR agonist ICI 204,448 inhibited chloroquine-induced pruritus in mice suggesting a peripheral pathway in itch suppression (50). Moreover, it was demonstrated that KOR immunostaining is down-regulated in the epidermis of atopic dermatitis (AD) and itchy psoriasis patients (35, 39). Psoralen plus ultraviolet A (PUVA) therapy did not lead to normal KOR levels in AD, but an increase in the KOR ligand DynA (35). Interestingly, KOR is up-regulated in the skin of patients with painful diseases such as fibromyalgia and painful scars (36, 51).

Kappa opioid receptor agonists in clinical use

The antipruritic effects of several artificial KOR agonists have been studied in rodents and monkeys, including models of histamine-, SP- and morphine-induced itch.
(43–49). Besides nalfurafine, all KOR agonists currently approved for therapeutic use in humans are mixed KOR agonists/MOR antagonists with similar receptor affinity-dependent side-effects of varying intensity. Nalbuphine, butorphanol and pentazocine are well known for their beneficial effects in acute morphine-induced pruritus (52–54). Only butorphanol and nalfurafine have been applied in chronic pruritus (Table I).

**Nalfurafine**

Nalfurafine (TRK-820) was developed in 1998 (55) and is a full agonist for the KOR, a partial agonist for the MOR and low-affinity antagonist for the nociceptin receptor (56). Compared with other synthetic KOR agonists, nalfurafine showed higher selectivity for KOR (46, 56). Nalfurafine has anti-nociceptive effects, as demonstrated in mice (e.g. hot plate test, tail flick test, tail pressure test) (57) and monkeys (58). The antipruritic effects of nalfurafine were investigated for the first time in 2002 (3). Pruritus induced by SP- and histamine was significantly inhibited by orally administered nalfurafine in mice, whereas antihistamines did not inhibit SP-induced itching (3). In the first multicentre, randomized, double-blind placebo-controlled trial, Wikström et al. (4) demonstrated significant clinical benefit of nalfurafine in humans with uraemic pruritus (n = 144) (Table I). The finding of reduced pruritus intensity was confirmed later in a similar cohort of patients, i.e. patients with uraemic pruritus, (n = 337) in a randomized placebo-controlled trial (8). Patients responded quickly to nalfurafine, after the first 7 days of treatment a considerable change inVAS was observed. Interestingly, the change in VAS was larger in treatment days 8–14 than in the first 7 days. This observation was independent of the dosage. In fact, 2.5 µg seemed to be almost equally effective as 5 µg. Uraemic itch is defined as a localized or generalized, chronic pruritus of almost unknown pathophysiology in patients with chronic renal failure and/or undergoing haemodialysis (4, 5). Given that an elevation of endogenous opioids has been postulated as a contributory factor, the antipruritic effects of nalfurafine in this indication may be specifically targeting the pathophysiology (4, 59–61). Nalfurafine is licensed only in Japan for the therapy of uraemic pruritus. There are studies on the use of nalfurafine in other pruritic diseases in animal models (e.g. atopic dermatitis) (44), but none on humans are available to date.

Evaluation of adverse events demonstrated nalfurafine to be well tolerated in clinical use. Common adverse drug reactions are mediated by the CNS (insomnia, somnolence, vertigo and headache) and the gastrointestinal system (constipation, nausea and vomiting). All events were transient and resolved without therapy discontinuation (4, 8) (Table II). There were no remarkable changes in haematology and blood chemistry or in vital signs/electrocardiography (8). Moderate transient increased prolactin, decreased blood thyroid stimulating hormone (TSH), decreased free testosterone, elevated eosinophils, transient elevation of aspartate aminotransferase and alanine transaminase were some of the adverse events observed (4, 8). Neither addiction nor symptoms of withdrawal were noted in nalfurafine-treated patients. Being a partial agonist for MOR and DOR, nalfurafine significantly reduced physical dependence on morphine in mice and humans (62).

**Table I. Effect of kappa-opioid receptors (KOR) agonists in chronic pruritus**

| Diagnosis | KOR agonists in studies (dosage; ref.) | Study design | n | Compared with | Effect |
|-----------|--------------------------------------|-------------|---|--------------|-------|
| Uraemic pruritus | Nalfurafine (5 µg i.v. 3/week for 2 or 4 weeks; 4) | RCT | 144 | Placebo | Significant improvement in pruritus (p<0.05) |
| | Nalfurafine (2.5 and 5 µg p.o. for 14 days; 8) | RCT | 337 | Placebo | Significant decrease in pruritus intensity on VAS (p<0.0001) |
| Prurigo nodularis | Butorphanol (1 mg/day; 70) | CR | 1 | – | Improvement |
| Primary biliary cirrhosis | Butorphanol (1 mg/day; 70) | CR | 1 | – | Improvement |
| Idiopathic pruritus in elderly patients | Butorphanol (1 mg/day; 70) | CR | 1 | – | Improvement |
| Non-Hodgkin’s lymphoma | Butorphanol (1 mg/day; 70) | CR | 1 | – | Improvement |
| Pruritus in chronic renal failure, diabetes (perforating collagenosis) | Butorphanol (1 mg/day; 70) | CR | 1 | – | Improvement |

CR: case report; RCT: randomized controlled trial; VAS: visual analogue scale; i.v.: intravenous; p.o.: per oral.

**Table II. Side-effects of therapy with the selective kappa-opioid receptor agonist nalfurafine**

| Incidence of >3% | Insomnia (14%) |
|-----------------|----------------|
| Moderate ADR in individual cases | Anorexia |
| | Headache |
| | Pruritus |
| | Sudden hearing loss |
| | Hypertension |
| | Vomiting |
| | Nausea |
| | Transient mood alterations (elevated mood, feeling abnormal) |
| | Decreased TSH |
| | Increased eosinophils |
| | Transient increase in prolactin |
| | Decrease in free testosterone |

TSH: thyroid stimulating hormone.
Butorphanol

Butorphanol, developed in the 1970s, is an injectable or intranasally applicable mixed KOR agonist/MOR antagonist, with analgesic potency higher than morphine, pethidine or pentazocine, and is administered to patients with acute postoperative pain (63–65). It relieves acute morphine-induced pruritus even in children (66, 67). However, prophylactic application of butorphanol before application of morphine does not prevent induction of pruritus (68). Moreover, butorphanol itself can induce acute pruritus (69) (Table III). An open-label uncontrolled study of butorphanol in single patients reported that the antipruritic effect of this drug sets in 1–4 days after nasal administration in elderly, primary biliary cirrhosis and non-Hodgkin’s lymphoma-associated pruritus (70). An impaired balance between MOR and KOR systems is suggested to have a role in cholestatic pruritus (71); furthermore, intranasal butorphanol was recommended in cholestatic pruritus, but not investigated in trials (72). A formulation containing 2 mg butorphanol tartrate in 100 µl purified water encapsulated into multilamellar phospholipid vesicles was topically used in rats and could be shown to penetrate the skin with low plasma levels (73). This formulation could potentially be used in the future to treat circumscribed pruritus and thus avoid systemic side-effects. Adverse effects of butorphanol are, for example, dizziness, sedation and nausea (64, 74). As with other morphine-like agents, respiratory depression can occur that is reversible in healthy subjects with moderate doses (up to 0.8 mg) of naloxone (64). Psychotomimetic reactions have been reported. Butorphanol is not recommended for use in patients dependent on narcotics. It should be used with caution in patients with increased intracranial pressure, disorders of respiratory function or control. In patients with hepatic or renal impairment, the initial dose of butorphanol should generally be half the recommended adult dose (e.g. 0.5 mg i.v.). Reproduction studies in animals (mice, rats and rabbits) did not reveal any teratogenic potential of butorphanol; however, it should be used with caution in pregnant and nursing women. There have been rare reports of infant respiratory distress/apnoea following the administration of butorphanol injection during labour. Mixed KOR agonists are not recommended for use in patients below 18 years of age.

CONCLUSION

KOR play an important role in pruritus and skin biology. Therefore, application of KOR agonists as systemic, and probably also topical, agents is a promising therapeutic approach to chronic pruritus. Clinical studies have demonstrated the efficacy of the KOR agonist nalfurafine in uraemic pruritus. Evidence from animal models and morphological studies in humans suggests that KOR agonists might also be effective in pruritus of other origin, for example atopic dermatitis.

ACKNOWLEDGEMENT

We thank Rajam Csordas for assistance in the preparation of the manuscript. The work was supported by Dr. August Wolff GmbH&Co.KG Arzneimittel.

REFERENCES

1. Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010; 63: 680–688.
2. Pan ZZ. mu-Opposing actions of the kappa-opioid receptor. Trend Pharmacol Sci 1998; 19: 94–98.
3. Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002; 435: 259–264.
4. Wikström B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005; 16: 3742–3747.
5. Mettang T, Pauli-Magnus C, Alshefr DM. Uraemic pruritus – new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17: 1558–1563.
6. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006; 7: 535–547.
7. Kumagai H, Matsukawa S, Utsumi J, Saruta T. Prospects for a novel kappa-opioid receptor agonist, TRK-820, in uremic pruritus. In: Yosipovitch G, editor. Itch. Basic mechanisms and therapy. New York: Marcel Dekker, 2004: p. 279–286.
8. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010; 25: 1251–1257.

9. Tseng RJ, Padgett DA, Dhabhar FS, Engler H, Sheridan JF. Stress-induced modulation of NK activity during influenza viral infection: role of glucocorticoids and opioids. Brain Behav Immun 2005; 19: 153–164.

10. Schwartz TW, Holst B. Molecular structure of G-protein-coupled receptors. In: Foreman JC, Johansen T, editors. Textbook of receptor pharmacology. New York: CRC Press, 2002: p. 81–110.

11. Satoh M, Minami M. Molecular pharmacology of the opioid receptor. Pharmacol Ther 1995; 68: 343–364.

12. Zadina JE, Martin-Schild S, Gerall AA, Kastin AJ, Hackler 12. Satoh M, Minami M. Molecular pharmacology of the opioid receptor agonists in regions of high mu-opiate receptor density. Ann NY Acad Sci 1999; 897: 136–144.

13. Stefano GB, Gounon Y, Casares F, Cadet P, Fricchione GL, Rialas C, et al. Endogenous morphine. Trends Neurosci 2000; 23: 436–442.

14. Goldstein A, Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol 1989; 36: 265–272.

15. Kosterlitz HW. The Wellcome Foundation lecture, 1982. Opioid peptides and their receptors. Proc R Soc Lond B Biol Sci 1985; 225: 27–40.

16. Kosterlitz HW, Paterson SJ, Robson LE. Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain. Br J Pharmacol 1981; 73: 939–949.

17. Zukin RS, Eghbali M, Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science 1986; 233: 774–776.

18. Dykstra LA, Gmerek DE, Winger G, Woods JH. Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 1987; 242: 413–420.

19. Liu-Chen LY. Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sci 2004; 75: 511–536.

20. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007; 127: 2228–2235.

21. Cheng B, Liu HW, Fu XB, Sheng ZY, Li JF. Coexistence and upregulation of three types of opioid receptors, delta, delta and kappa, in human hypertrophic scars. Br J Dermatol 2008; 158: 713–720.

22. Salami S, Aeschlimann A, Reisch N, Jungel A, Gay RE, Heppner FL, et al. Detection of kappa and delta opioid receptors in skin – outside the nervous system. Biochem Biophys Res Commun 2005; 338: 1012–1017.

23. Bigiardi-Qi M, Gavieraux-Ruff C, Pfaltz K, Bady P, Baumann T, Rufl T, et al. Deletion of mu- and kappa-opioid receptors in mice changes epidural hypertherpy, density of peripheral nerve endings, and itch behavior. J Invest Dermatol 2007; 127: 1479–1488.

24. Taneda K, Tominaga M, Negi O, Tengara S, Kamo A, Ogawa H et al. Evaluation of epidural nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol 2011; 165: 277–284.

25. Messmer D, Hatsukari I, Hitosugi N, Schmidt-Wolf IG, Singhal PC. Morphine reciprocally regulates IL-10 and IL-12 production by monocye-derived human dendritic cells and enhances T cell activation. Mol Med 2006; 12: 284–290.

26. Finley MJ, Chen X, Bardi G, Davey P, Geller EB, Zhang L, et al. Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor. J Neuroimmunol 2008; 197: 114–123.

27. Calebi K, Nagase H. Norbinaltorphimine, a selective kappa-opioid receptor agonist, induces an itch-associated response in mice. Eur J Pharmacol 2001; 418: 141–145.

28. Kamei J, Inan S, Dun NJ, Cowan A. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicted scratching behavior in mice. Neuroscience 2009; 158: 713–720.
44. Nakao K, Ikeda K, Kurokawa T, Togashi Y, Umeuchi H, Honda T, et al. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis.] Nihon Shinkei Seishin Yakurigaku Zasshi 2008; 28: 75–83 (in Japanese).

45. Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, et al. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003; 477: 29–35.

46. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, et al. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinoceptive activities in vivo. J Pharmacol Exp Ther 2005; 312: 220–230.

47. Umeuchi H, Kawashima Y, Aoki CA, Kurokawa T, Nakao K, Itoh M, et al. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel kappa-opioid receptor agonist nalfurafine hydrochloride. Eur J Pharmacol 2005; 518: 133–139.

48. Inan S, Cowan A. Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats. Pharmacol Biochem Behav 2006; 85: 39–43.

49. Watanabe S, Hasebe K, Yoshikawa S, Ikeda K, Hirakata M, Miyamoto Y, et al. Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist.] Nihon Shinkei Seishin Yakurigaku Zasshi 2010; 30: 185–191 (in Japanese).

50. Tsuji M, Takeda H, Matsumiya T, Nagase H, Yamazaki M, Narita M, et al. A novel kappa-opioid receptor agonist, TRK-820, blocks the development of physical dependence on morphine in mice. Life Sci 2000; 66: 353–358.

51. Delpizzo A. Butorphanol, a new intravenous analgesic: double-blind comparison with morphine sulfate in postoperative patients with moderate or severe pain. Curr Ther Res Clin Exp 1976; 20: 221–232.

52. Heel RC, Brogden RN, Speight TM, Avery GS. Butorphanol: a review of its pharmacological properties and therapeutic efficacy. Drugs 1978; 16: 473–505.

53. Sazavova A, Sadhasivam S, Wang Y, Nick TG, Goldschneider K. Comparison of postoperative analgesia with epidural butorphanol/bupivacaine versus fentanyl/bupivacaine following pediatric urological procedures. J Opioid Manag 2010; 6: 401–407.

54. Gunter JB, McAuliffe J, Gregg T, Weidner N, Varughese AM, Sweeney DM. Continuous epidural butorphanol relieves pruritus associated with epidural morphine infusions in children. Paediatr Anaesth 2000; 10: 167–172.

55. Yokoyama Y, Yokoyama T, Nagao Y, Nakagawa T, Magaribuchi T. [Treatment of epidural morphine induced pruritus with butorphanol.] Masui 2009; 58: 178–182 (in Japanese).

56. Sakai T, Fukano T, Sumikawa K. IV butorphanol reduces analgesia but not pruritus or nausea associated with intra-thecal morphine. Can J Anaesth 2001; 48: 831–832.

57. Bernstein JE, Grinzi RA. Butorphanol-induced pruritus antagonized by naloxone. J Am Acad Dermatol 1981; 5: 227–228.

58. Dawn AG, Yoshiyovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54: 527–531.

59. Inan S, Cowan A. Reduced kappa-opioid activity in a rat model of cholestasis. Eur J Pharmacol 2005; 518: 182–186.

60. Bergasa NV. Treatment of the pruritus of cholestasis. Curr Treat Options Gastroenterol 2004; 7: 501–508.

61. Lim GJ, Ishiiy Y, Dawn A, Harrison B, Kim do W, Atala A, et al. In vitro and in vivo characterization of a novel liposomal butorphanol formulation for treatment of pruritus. Acta Derm Venereol 2008; 88: 327–330.

62. Olsen JC, McGrath NA, Schwarz DG, Cutchliffe BJ, Stern JL. A double-blind randomized clinical trial evaluating the analgesic efficacy of ketorolac versus butorphanol for patients with suspected biliary colic in the emergency department. Acad Emerg Med 2008; 15: 718–722.